"postauthorization" meaning in English

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "post-",
        "3": "authorization"
      },
      "expansion": "post- + authorization",
      "name": "affix"
    }
  ],
  "etymology_text": "From post- + authorization.",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "postauthorization (not comparable)",
      "name": "en-adj"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "adj",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms prefixed with post-",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        }
      ],
      "examples": [
        {
          "text": "Coordinate term: preauthorization"
        },
        {
          "ref": "2016, H. Guenter Hennings, “Postmarketing Evaluation”, in Anthony C. Cartwright, Brian R. Matthews, editors, International Pharmaceutical Product Registration (Drugs and the Pharmaceutical Sciences; 200), 2nd edition, Boca Raton, FL: CRC Press, →ISBN, page 594:",
          "text": "The MAH may be required by the FDA to conduct postauthorization studies concerning clinical safety, clinical efficacy, clinical pharmacology, or nonclinical toxicology.",
          "type": "quote"
        }
      ],
      "glosses": [
        "After authorization."
      ],
      "id": "en-postauthorization-en-adj-l4C4p1OL",
      "links": [
        [
          "authorization",
          "authorization"
        ]
      ],
      "tags": [
        "not-comparable"
      ]
    }
  ],
  "word": "postauthorization"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "post-",
        "3": "authorization"
      },
      "expansion": "post- + authorization",
      "name": "affix"
    }
  ],
  "etymology_text": "From post- + authorization.",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "postauthorization (not comparable)",
      "name": "en-adj"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "adj",
  "senses": [
    {
      "categories": [
        "English adjectives",
        "English entries with incorrect language header",
        "English lemmas",
        "English terms prefixed with post-",
        "English terms with quotations",
        "English uncomparable adjectives",
        "Pages with 1 entry",
        "Pages with entries"
      ],
      "examples": [
        {
          "text": "Coordinate term: preauthorization"
        },
        {
          "ref": "2016, H. Guenter Hennings, “Postmarketing Evaluation”, in Anthony C. Cartwright, Brian R. Matthews, editors, International Pharmaceutical Product Registration (Drugs and the Pharmaceutical Sciences; 200), 2nd edition, Boca Raton, FL: CRC Press, →ISBN, page 594:",
          "text": "The MAH may be required by the FDA to conduct postauthorization studies concerning clinical safety, clinical efficacy, clinical pharmacology, or nonclinical toxicology.",
          "type": "quote"
        }
      ],
      "glosses": [
        "After authorization."
      ],
      "links": [
        [
          "authorization",
          "authorization"
        ]
      ],
      "tags": [
        "not-comparable"
      ]
    }
  ],
  "word": "postauthorization"
}